Gerardo Nardone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1602376/publications.pdf

Version: 2024-02-01

71061 102432 5,453 146 41 66 citations h-index g-index papers 150 150 150 7337 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 471-476.	1.1	358
2	The human gastric microbiota: Is it time to rethink the pathogenesis of stomach diseases?. United European Gastroenterology Journal, 2015, 3, 255-260.	1.6	181
3	Alcoholic disease: Liver and beyond. World Journal of Gastroenterology, 2014, 20, 14652.	1.4	173
4	Coeliac disease and unfavourable outcome of pregnancy. Gut, 2000, 46, 332-335.	6.1	166
5	The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Alimentary Pharmacology and Therapeutics, 1999, 13, 1429-1436.	1.9	149
6	Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut, 2010, 59, 1465-1470.	6.1	132
7	Helicobacter pylori and molecular events in precancerous gastric lesions. Alimentary Pharmacology and Therapeutics, 2004, 20, 261-270.	1.9	128
8	Loss-of-Function of the Voltage-Gated Sodium Channel NaV1.5 (Channelopathies) in Patients With Irritable Bowel Syndrome. Gastroenterology, 2014, 146, 1659-1668.	0.6	120
9	Functional variants in the sucrase–isomaltase gene associate with increased risk of irritable bowel syndrome. Gut, 2018, 67, 263-270.	6.1	120
10	Effects of long-term PPI treatment on producing bowel symptoms and SIBO. European Journal of Clinical Investigation, 2011, 41, 380-386.	1.7	103
11	Increased mucosal nitric oxide production in ulcerative colitis is mediated in part by the enteroglialâ€derived S100B protein. Neurogastroenterology and Motility, 2009, 21, 1209.	1.6	102
12	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67, 1784-1796.	3.6	93
13	Enteric Glial-Derived S100B Protein Stimulates Nitric Oxide Production in Celiac Disease. Gastroenterology, 2007, 133, 918-925.	0.6	86
14	Protective effects of Lactobacillus paracase iF19 in a rat model of oxidative and metabolic hepatic injury. American Journal of Physiology - Renal Physiology, 2010, 299, G669-G676.	1.6	83
15	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 65-71.	1.8	83
16	Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterology, 2017, 17, 53.	0.8	83
17	In Vitro-Deranged Intestinal Immune Response to Gliadin in Type 1 Diabetes. Diabetes, 2004, 53, 1680-1683.	0.3	82
18	Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection. Gastroenterology, 2012, 143, 55-61.e1.	0.6	81

#	Article	IF	CITATIONS
19	Expression of COX-2, mPGE-synthase1, MDR-1(P-gp), and Bcl-xL: a molecular pathway ofH pylori-related gastric carcinogenesis. Journal of Pathology, 2004, 202, 305-312.	2.1	80
20	A microbiota-centric view of diseases of the upper gastrointestinal tract. The Lancet Gastroenterology and Hepatology, 2017, 2, 298-312.	3.7	77
21	Nutritional state and energy balance in cirrhotic patients with or without hypermetabolismâ~†Multicentre prospective study by the â€`Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease, 2005, 37, 681-688.	0.4	76
22	Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clinical Gastroenterology and Hepatology, 2003, 1, 273-278.	2.4	73
23	An immunodominant DQ8 restricted gliadin peptide activates small intestinal immune response in in vitro cultured mucosa from HLA-DQ8 positive but not HLA-DQ8 negative coeliac patients. Gut, 2003, 52, 57-62.	6.1	73
24	Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality. Journal of Hepatology, 2021, 75, 728-729.	1.8	72
25	The changing scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2021, 41, 585-597.	1.9	69
26	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2017, 37, 259-270.	1.9	67
27	Increased Prevalence of Rare Sucrase-isomaltase PathogenicÂVariants in Irritable Bowel Syndrome Patients. Clinical Gastroenterology and Hepatology, 2018, 16, 1673-1676.	2.4	64
28	Large Brunner's gland adenoma: Case report and literature review. World Journal of Gastroenterology, 2006, 12, 1966.	1.4	59
29	CD133 and CD44 Cell surface markers do not identify cancer stem cells in primary human gastric tumors. Journal of Cellular Physiology, 2012, 227, 2686-2693.	2.0	59
30	Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of. Clinical Gastroenterology and Hepatology, 2003, 1, 273-278.	2.4	59
31	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut, 2023, 72, 141-152.	6.1	57
32	The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. United European Gastroenterology Journal, 2017, 5, 944-953.	1.6	55
33	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology, 2018, 155, 168-179.	0.6	55
34	Focus on acute diarrhoeal disease. World Journal of Gastroenterology, 2009, 15, 3341.	1.4	55
35	The Gut Bacteria-Driven Obesity Development. Digestive Diseases, 2016, 34, 221-229.	0.8	53
36	Diet, <i>H pylori </i> infection and gastric cancer: Evidence and controversies. World Journal of Gastroenterology, 2007, 13, 2901.	1.4	50

#	Article	IF	Citations
37	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2016, 17, 1225.	1.8	50
38	Gastrokine 1 expression in patients with and without Helicobacter pylori infection. Digestive and Liver Disease, 2007, 39, 122-129.	0.4	49
39	Contribution of Gut Microbiota to Colonic and Extracolonic Cancer Development. Digestive Diseases, 2011, 29, 554-561.	0.8	48
40	Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. Journal of Clinical Pathology, 2011, 64, 677-682.	1.0	46
41	<i>Helicobacter pylori</i> and Epigenetic Mechanisms Underlying Gastric Carcinogenesis. Digestive Diseases, 2007, 25, 225-229.	0.8	43
42	Vascular endothelial growth factor and neo-angiogenesis inH. pylori gastritis in humans. Journal of Pathology, 2005, 207, 277-284.	2.1	42
43	Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments. American Journal of Gastroenterology, 2002, 97, 2756-2762.	0.2	41
44	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver International, 2019, 39, 1478-1489.	1.9	41
45	Reflux oesophagitis in adult coeliac disease: beneficial effect of a gluten free diet. Gut, 2003, 52, 514-517.	6.1	39
46	Molecular expression of Gastrokine 1 in normal mucosa and in Helicobacter pylori-related preneoplastic and neoplastic gastric lesions. Cancer Biology and Therapy, 2008, 7, 1890-1895.	1.5	39
47	Effects of carbonated water on functional dyspepsia and constipation. European Journal of Gastroenterology and Hepatology, 2002, 14, 991-999.	0.8	38
48	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. Journal of Gastrointestinal Surgery, 2018, 22, 859-871.	0.9	38
49	Gastroduodenal Lesions and Helicobacter pylori Infection in Dyspeptic Patients With and Without Chronic Renal Failure. Helicobacter, 2005, 10, 53-58.	1.6	37
50	Long acting release-octreotide as "rescue―therapy to control angiodysplasia bleeding: A retrospective study of 98 cases. Digestive and Liver Disease, 2014, 46, 688-694.	0.4	36
51	Characterization of the Duodenal Mucosal Microbiome in Obese Adult Subjects by 16S rRNA Sequencing. Microorganisms, 2020, 8, 485.	1.6	36
52	Helicobacter pylori and gastric malignancies. Helicobacter, 2003, 8, 44-52.	1.6	34
53	MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Laboratory Investigation, 2012, 92, 1407-1418.	1.7	34
54	Gastric Normal Adjacent Mucosa Versus Healthy and Cancer Tissues: Distinctive Transcriptomic Profiles and Biological Features. Cancers, 2019, 11, 1248.	1.7	34

#	Article	IF	CITATIONS
55	Lipids of human gastric mucosa: Effect of Helicobacter pylori infection and nonalcoholic cirrhosis. Gastroenterology, 1994, 107, 362-368.	0.6	33
56	Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions. World Journal of Gastrointestinal Oncology, 2012, 4, 54.	0.8	31
57	Evaluation of a commercial serological kit for detection of salivary immunoglobulin G to Helicobacter pylori. European Journal of Gastroenterology and Hepatology, 2000, 12, 1117-1120.	0.8	30
58	Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) — Study section "Digestive Diseases in Primary Care― Digestive and Liver Disease, 2018, 50, 894-902.	0.4	30
59	Vascular Endothelial Growth Factor and Cyclooxygenase-2 are Overexpressed in Ileal Pouch-Anal Anastomosis. Diseases of the Colon and Rectum, 2007, 50, 650-659.	0.7	29
60	Reproducibility of shear wave elastography (SWE) in patients with chronic liver disease. PLoS ONE, 2017, 12, e0185391.	1.1	29
61	Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clinical Gastroenterology and Hepatology, 2003, 1, 273-8.	2.4	28
62	Investigation of intestine function during acute viral hepatitis using combined sugar oral loads Gut, 1987, 28, 1439-1444.	6.1	27
63	Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinomaâ€associated chronic atrophic gastritis. United European Gastroenterology Journal, 2017, 5, 37-44.	1.6	27
64	Long-lasting intestinal bleeding in an old patient with multiple mucosal vascular abnormalities and Glanzmann's thrombasthenia: 3-year pharmacological management. Journal of Internal Medicine, 2002, 252, 271-275.	2.7	26
65	Probiotics. Journal of Clinical Gastroenterology, 2004, 38, S121-S122.	1.1	26
66	Epigenetic alterations due to diet and <i> Helicobacter pylori </i> infection in gastric carcinogenesis. Expert Review of Gastroenterology and Hepatology, 2008, 2, 243-248.	1.4	26
67	Vitamin B12supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut, 2013, 62, 766-773.	6.1	26
68	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology, 2018, 68, 1232-1244.	3.6	26
69	Tissue ghrelin level and gastric emptying rate in adult patients with celiac disease. Neurogastroenterology and Motility, 2008, 20, 884-890.	1.6	25
70	Modeling costâ€effectiveness and health gains of a "universal―versus "prioritized―hepatitis C virus treatment policy in a realâ€life cohort. Hepatology, 2017, 66, 1814-1825.	3.6	25
71	Twice-Daily Standard Dose of Omeprazole Achieves the Necessary Level of Acid Inhibition for Helicobacter pylori Eradication. A Randomized Controlled Trial Using Standard and Double Doses of Omeprazole in Triple Therapy. Digestive Diseases and Sciences, 2005, 50, 443-448.	1.1	24
72	Barrett's esophagus: prevalence–incidence and etiology–origins. Annals of the New York Academy of Sciences, 2011, 1232, 1-17.	1.8	24

#	Article	IF	CITATIONS
73	In Vivo and In Vitro Studies of Cytosolic Phospholipase A2 Expression in Helicobacter pyloriInfection. Infection and Immunity, 2001, 69, 5857-5863.	1.0	23
74	A Mannose-Binding Lectin-Defective Haplotype Is a Risk Factor for Gastric Cancer. Clinical Chemistry, 2006, 52, 1625-1627.	1.5	22
75	Quality of bowel cleansing in hospitalized patients undergoing colonoscopy: A multicentre prospective regional study. Digestive and Liver Disease, 2015, 47, 669-674.	0.4	22
76	Intestinal amyloidosis: Two cases with different patterns of clinical and imaging presentation. World Journal of Gastroenterology, 2010, 16, 2566.	1.4	22
77	Interleukin-13 mucosal production in Helicobacter pylori-related gastric diseases. Digestive and Liver Disease, 2008, 40, 240-247.	0.4	21
78	Gastric Cancerâ€"Epidemiologic and Clinical Aspects. Helicobacter, 2014, 19, 32-37.	1.6	21
79	Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 922-932.	3.7	21
80	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 57-66.	0.5	21
81	Nonâ€bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A realâ€life study. Helicobacter, 2020, 25, e12694.	1.6	20
82	Up-regulation of heparin binding epidermal growth factor-like growth factor and amphiregulin expression in Helicobacter pylori-infected human gastric mucosa. Digestive and Liver Disease, 2002, 34, 498-505.	0.4	19
83	Chemoprevention of Gastric Cancer: Role of COX-2 Inhibitors and Other Agents. Digestive Diseases, 2004, 22, 320-326.	0.8	19
84	Lowâ \in dose aspirin reduces the gene expression of gastrokineâ \in 1 in the antral mucosa of healthy subjects. Alimentary Pharmacology and Therapeutics, 2008, 28, 782-788.	1.9	19
85	Green tea polyphenols affect invasiveness of human gastric MKN-28 cells by inhibition of LPS or TNF-α induced Matrix Metalloproteinase-9/2. Biochimie Open, 2016, 3, 56-63.	3.2	19
86	Increased COX-2, But Not COX-1, mRNA Expression in Helicobacter pylori Gastritis. American Journal of Gastroenterology, 1999, 94, 3376-3378.	0.2	18
87	Increased severity of dyspeptic symptoms related to mental stress is associated with sympathetic hyperactivity and enhanced endocrine response in patients with postprandial distress syndrome. Neurogastroenterology and Motility, 2013, 25, 31.	1.6	18
88	The Psyche and Gastric Functions. Digestive Diseases, 2014, 32, 206-212.	0.8	18
89	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1123-1130.	1.4	18
90	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	1.7	18

#	Article	IF	Citations
91	Screening for and surveillance of gastric cancer. World Journal of Gastroenterology, 2014, 20, 13681.	1.4	18
92	Incidence and distribution of coeliac disease in Campania (Italy): 2011–2013. United European Gastroenterology Journal, 2015, 3, 182-189.	1.6	17
93	Effect of Helicobacter pylori infection on gastric cell proliferation and genomic instablity in a paediatric population of Southern Italy. Digestive and Liver Disease, 2001, 33, 743-749.	0.4	16
94	Apoptosis and Cytologic Differentiation in Hepatocellular Carcinoma on Fine Needle Aspiration Samples. Acta Cytologica, 1996, 40, 861-866.	0.7	15
95	Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease, 2018, 50, 542-548.	0.4	15
96	Gastric Emptying Time, Esophageal pH-Impedance Parameters, Quality of Life, and Gastrointestinal Comorbidity in Obese Children and Adolescents. Journal of Pediatrics, 2018, 194, 94-99.	0.9	15
97	Lymphoblastoid interferon in chronic hepatitis C patients, †non-responders' to recombinant interferon-α (rIFN-α). Journal of Hepatology, 1992, 14, 419-420.	1.8	14
98	Diagnosis of chronic atrophic gastritis by morphometric image analysis. A new method to overcome the confounding effect of the inflammatory infiltrate. Journal of Pathology, 2002, 198, 47-54.	2.1	14
99	13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C. Journal of Hepatology, 2012, 56, 782-787.	1.8	14
100	Duodenal Metatranscriptomics to Define Human and Microbial Functional Alterations Associated with Severe Obesity: A Pilot Study. Microorganisms, 2020, 8, 1811.	1.6	13
101	Gastrointestinal sensitivity and gastroesophageal reflux disease. Annals of the New York Academy of Sciences, 2013, 1300, 80-95.	1.8	12
102	Pegylated interferon \hat{l}_{\pm} plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. Digestive and Liver Disease, 2014, 46, 826-832.	0.4	12
103	Loss of Expression of Tumor Suppressor p16 ^{INK4} Protein in Human Primary Gastric Cancer Is Related to the Grade of Differentiation. Digestive Diseases, 2002, 20, 102-105.	0.8	11
104	Histological heterogeneity and somatic mtDNA mutations in gastric intraepithelial neoplasia. Modern Pathology, 2008, 21, 733-741.	2.9	11
105	Sweetened carbonated drinks do not alter upper digestive tract physiology in healthy subjects. Neurogastroenterology and Motility, 2008, 20, 780-789.	1.6	11
106	Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: A randomized clinical trial. Digestive and Liver Disease, 2015, 47, 273-279.	0.4	11
107	Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Frontiers in Cell and Developmental Biology, 2021, 9, 748253.	1.8	11
108	Treatment Options for Uncomplicated Diverticular Disease of the Colon. Journal of Clinical Gastroenterology, 2009, 43, 803-808.	1.1	10

#	Article	IF	CITATIONS
109	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021, 41, 396-407.	1.9	10
110	Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection. Digestive and Liver Disease, 2003, 35, 151-156.	0.4	9
111	Prognostic performance of the †DICA†endoscopic classification and the †CODA†score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study. Gut, 2022, 71, 1350-1358.	6.1	9
112	Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract. Pharmaceuticals, 2010, 3, 2495-2516.	1.7	8
113	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. International Journal of Biological Markers, 2021, 36, 54-61.	0.7	8
114	Small intestinal bacterial overgrowth. Digestive and Liver Disease Supplements, 2009, 3, 44-49.	0.2	7
115	Low expression of human \hat{I}^2 -defensin 1 in duodenum of celiac patients is partially restored by a gluten-free diet. Clinical Chemistry and Laboratory Medicine, 2010, 48, 489-492.	1.4	7
116	MIB2variants altering NOTCH signalling result in left ventricle hypertrabeculation/non-compaction and are associated with Ménétrier-like gastropathy. Human Molecular Genetics, 2016, 26, ddw365.	1.4	7
117	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study Digestive and Liver Disease, 2021, 53, 1011-1019.	0.4	7
118	Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease. IDCases, 2019, 17, e00537.	0.4	6
119	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer, 2021, 10, 126-136.	4.2	6
120	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers, 2021, 13, 2677.	1.7	6
121	The "DICA―Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 23-27.	0.5	6
122	Barrett's esophagus: prevalence and incidence of adenocarcinomas. Annals of the New York Academy of Sciences, 2011, 1232, 230-247.	1.8	5
123	Tissue resistance in the normal and diseased esophagus. Annals of the New York Academy of Sciences, 2013, 1300, 200-212.	1.8	5
124	Gastric Emptying Impacts the Timing of Meal Glucose Peak in Subjects With Uncomplicated Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2269-2276.	1.8	5
125	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. Cancers, 2021, 13, 592.	1.7	5
126	Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold. Digestive Diseases, 2022, 40, 123-132.	0.8	5

#	Article	IF	Citations
127	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Frontiers in Oncology, 2022, 12, 822507.	1.3	5
128	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk―patients does not further improve survival. Digestive and Liver Disease, 2022, 54, 927-936.	0.4	4
129	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	1.3	4
130	Impact of proton pump inhibitors on cytochrome P450 activity assessed by ¹³ Câ€aminopyrine breath test in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2021, 53, 608-615.	1.9	4
131	Is Screening for and Surveillance of Atrophic Gastritis Advisable?. Digestive Diseases, 2007, 25, 214-217.	0.8	3
132	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.4	3
133	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.4	2
134	Blinded Oral Challenges with Lactose and Placebo Accurately Diagnose Lactose Intolerance: A Real-Life Study. Nutrients, 2021, 13, 1653.	1.7	2
135	Recalibrating survival prediction among patients receiving transâ€arterial chemoembolization for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 45-53.	0.2	2
136	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 39-44.	0.5	2
137	An unusual case of high alpha-fetoprotein level and liver masses. Digestive and Liver Disease, 2008, 40, 224.	0.4	1
138	Course of the Diverticular Disease: What is changing?. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 11-16.	0.5	1
139	Could immunostimulant drugs be useful in apparently medically refractory Crohn's disease?. Digestive Diseases and Sciences, 1994, 39, 661-662.	1.1	0
140	16 Role of Helicobacter pylori in Gastric Cancer. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 4, 205-220.	0.0	0
141	Preface. Digestive Diseases, 2011, 29, 517-517.	0.8	0
142	Reply to: "Prediction of liver fibrosis progression by non-invasive tests in chronic hepatitis C: The impact of validationâ€. Journal of Hepatology, 2013, 58, 832.	1.8	0
143	Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis. Digestive Diseases and Sciences, 2021, 66, 408-411.	1.1	O
144	Medical Management of Eating Disorders. Annals of Internal Medicine, 2005, 142, 804.	2.0	0

ı	#	Article	IF	CITATIONS
	145	Editorial: proton pump inhibitor use in cirrhosisâ€"a piece of the puzzle. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 665-666.	1.9	0
	146	Wernicke Encephalopathy in Ulcerative Colitis. Inflammatory Bowel Diseases, 2022, 28, e70-e71.	0.9	0